Rocapuldencel-T

DB17588InvestigationalVaccines

Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer).

Mechanism: Pharmacologically active on CD40 ligand
Curator reviewed
Code names: AGS-003

Resolves to

Compound

UNII8I9S6401XZ

Targets

P29965CD40LG

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rocapuldencel-T, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account